Menu
Back to User profile » Dr Thomas J. Dengler
Papers published by Dr Thomas J. Dengler:
Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:447-457
Published Date: 12 May 2014
Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA
Drug Design, Development and Therapy 2013, 7:1323-1328
Published Date: 5 November 2013
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2013, 7:1253-1258
Published Date: 21 October 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:297-303
Published Date: 8 April 2013
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2012, 6:289-295
Published Date: 12 October 2012